Your session is about to expire
← Back to Search
Behavioural Intervention
Brain Stimulation for Nicotine Addiction in Schizophrenia
N/A
Recruiting
Led By Heather B Ward, MD
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to one week, and three weeks to five weeks
Awards & highlights
Summary
"This trial aims to compare two types of brain stimulation in nicotine users with and without psychosis to see if it can change brain connections related to nicotine use and if it affects cravings. Participants will undergo cognitive tests
Who is the study for?
This trial is for individuals who use nicotine and have schizophrenia, as well as those without a psychotic disorder. Participants should be interested in how brain stimulation might help with nicotine cravings.
What is being tested?
The study tests two types of transcranial magnetic stimulation (rTMS) to see if they can alter brain activity related to nicotine use and reduce cravings. It compares the effects on people with and without psychosis.
What are the potential side effects?
rTMS may cause discomfort at the site of application, headache, lightheadedness, or seizures in rare cases. Most side effects are mild and temporary.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to one week, and three weeks to five weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to one week, and three weeks to five weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Cue-induced craving
Resting-state functional connectivity
Self-reported craving
+1 moreSecondary outcome measures
Fagerstrom Test for Nicotine Dependence (FTND)
Self-reported nicotine use
Wisconsin Smoking Withdrawal Scale (WSWS)
Trial Design
2Treatment groups
Active Control
Group I: L DLPFC-Targeted iTBS, Then DMN-Targeted cTBSActive Control1 Intervention
Participants will first receive intermittent theta burst stimulation (iTBS) at 100% active motor threshold (AMT) anatomically targeted to the left dorsolateral prefrontal cortex for five consecutive days. iTBS will be administered in a pattern consisting of 2s trains of 3 pulses at 50Hz, repeated at 5Hz, every 10s for a total of 600 pulses. There will then be a washout period of at least two weeks before starting the DMN-Targeted cTBS. Participants will then receive continuous theta burst stimulation (cTBS) at 100% AMT targeted to an individual-specific map of the left parietal node of the default mode network for five consecutive days. cTBS will be administered in a pattern consisting of 1 60s train of 3 pulses at 50Hz, repeated at 5Hz, for a total of 600 pulses.
Group II: DMN-Targeted cTBS, Then L DLPFC-Targeted iTBSActive Control1 Intervention
Participants will first receive continuous theta burst stimulation (cTBS) at 100% AMT targeted to an individual-specific map of the left parietal node of the default mode network for five consecutive days. cTBS will be administered in a pattern consisting of 1 60s train of 3 pulses at 50Hz, repeated at 5Hz, for a total of 600 pulses. There will then be a washout period of at least two weeks before starting the L DLPFC-Targeted iTBS. Participants will receive intermittent theta burst stimulation (iTBS) at 100% active motor threshold (AMT) anatomically targeted to the left dorsolateral prefrontal cortex for five consecutive days. iTBS will be administered in a pattern consisting of 2s trains of 3 pulses at 50Hz, repeated at 5Hz, every 10s for a total of 600 pulses.
Find a Location
Who is running the clinical trial?
Vanderbilt University Medical CenterLead Sponsor
888 Previous Clinical Trials
934,834 Total Patients Enrolled
5 Trials studying Schizophrenia
169 Patients Enrolled for Schizophrenia
Heather B Ward, MDPrincipal InvestigatorVanderbilt University Medical Center
1 Previous Clinical Trials
Share this study with friends
Copy Link
Messenger